IMA203

BIOLOGICAL4 trials

Sponsors

Immatics US Inc., Immatics US, Inc.

Conditions

Cutaneous MelanomaMelanoma, Cutaneous MalignantSolid tumorsSynovial Sarcomacutaneous malignantmelanoma

Phase 1

Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)

RecruitingCTIS2024-515114-41-00

Immatics US Inc.Solid tumors

Start: 2020-08-10Target: 272Updated: 2025-12-29

ACTengine® IMA203 Combined With mRNA-4203

RecruitingNCT06946225

Immatics US, Inc.Cutaneous Melanoma, Synovial Sarcoma

Start: 2025-07-25End: 2029-08-31Target: 15Updated: 2026-01-08

Phase 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

RecruitingNCT06743126

Immatics US, Inc.Melanoma, Cutaneous Malignant

Start: 2025-01-14End: 2031-10-01Target: 360Updated: 2026-03-19

A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)

RecruitingCTIS2024-517062-42-00

Immatics US Inc.cutaneous malignant, melanoma

Start: 2025-05-02Target: 84Updated: 2025-12-18

Related Papers

Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.

Journal of Clinical Oncology2025-05-28

SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.

Journal of Clinical Oncology2025-05-28

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Nature Medicine2025-04-0924 citations